These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32492700)

  • 1. HHEX promotes myeloid transformation in cooperation with mutant ASXL1.
    Takeda R; Asada S; Park SJ; Yokoyama A; Becker HJ; Kanai A; Visconte V; Hershberger C; Hayashi Y; Yonezawa T; Tamura M; Fukushima T; Tanaka Y; Fukuyama T; Matsumoto A; Yamasaki S; Nakai K; Yamazaki S; Inaba T; Shibata T; Inoue D; Honda H; Goyama S; Maciejewski JP; Kitamura T
    Blood; 2020 Oct; 136(14):1670-1684. PubMed ID: 32492700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
    Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
    J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation.
    Nagase R; Inoue D; Pastore A; Fujino T; Hou HA; Yamasaki N; Goyama S; Saika M; Kanai A; Sera Y; Horikawa S; Ota Y; Asada S; Hayashi Y; Kawabata KC; Takeda R; Tien HF; Honda H; Abdel-Wahab O; Kitamura T
    J Exp Med; 2018 Jun; 215(6):1729-1747. PubMed ID: 29643185
    [No Abstract]   [Full Text] [Related]  

  • 4. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis.
    Asada S; Goyama S; Inoue D; Shikata S; Takeda R; Fukushima T; Yonezawa T; Fujino T; Hayashi Y; Kawabata KC; Fukuyama T; Tanaka Y; Yokoyama A; Yamazaki S; Kozuka-Hata H; Oyama M; Kojima S; Kawazu M; Mano H; Kitamura T
    Nat Commun; 2018 Jul; 9(1):2733. PubMed ID: 30013160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
    Inoue D; Kitaura J; Matsui H; Hou HA; Chou WC; Nagamachi A; Kawabata KC; Togami K; Nagase R; Horikawa S; Saika M; Micol JB; Hayashi Y; Harada Y; Harada H; Inaba T; Tien HF; Abdel-Wahab O; Kitamura T
    Leukemia; 2015 Apr; 29(4):847-57. PubMed ID: 25306901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.
    Yang H; Kurtenbach S; Guo Y; Lohse I; Durante MA; Li J; Li Z; Al-Ali H; Li L; Chen Z; Field MG; Zhang P; Chen S; Yamamoto S; Li Z; Zhou Y; Nimer SD; Harbour JW; Wahlestedt C; Xu M; Yang FC
    Blood; 2018 Jan; 131(3):328-341. PubMed ID: 29113963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
    Abdel-Wahab O; Adli M; LaFave LM; Gao J; Hricik T; Shih AH; Pandey S; Patel JP; Chung YR; Koche R; Perna F; Zhao X; Taylor JE; Park CY; Carroll M; Melnick A; Nimer SD; Jaffe JD; Aifantis I; Bernstein BE; Levine RL
    Cancer Cell; 2012 Aug; 22(2):180-93. PubMed ID: 22897849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model.
    Hsu YC; Chiu YC; Lin CC; Kuo YY; Hou HA; Tzeng YS; Kao CJ; Chuang PH; Tseng MH; Hsiao TH; Chou WC; Tien HF
    J Hematol Oncol; 2017 Jul; 10(1):139. PubMed ID: 28697759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
    Asada S; Kitamura T
    Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-level GATA2 overexpression promotes myeloid progenitor self-renewal and blocks lymphoid differentiation in mice.
    Nandakumar SK; Johnson K; Throm SL; Pestina TI; Neale G; Persons DA
    Exp Hematol; 2015 Jul; 43(7):565-77.e1-10. PubMed ID: 25907033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway.
    Fujino T; Goyama S; Sugiura Y; Inoue D; Asada S; Yamasaki S; Matsumoto A; Yamaguchi K; Isobe Y; Tsuchiya A; Shikata S; Sato N; Morinaga H; Fukuyama T; Tanaka Y; Fukushima T; Takeda R; Yamamoto K; Honda H; Nishimura EK; Furukawa Y; Shibata T; Abdel-Wahab O; Suematsu M; Kitamura T
    Nat Commun; 2021 Mar; 12(1):1826. PubMed ID: 33758188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NKL homeobox gene activities in normal and malignant myeloid cells.
    Nagel S; Scherr M; MacLeod RAF; Pommerenke C; Koeppel M; Meyer C; Kaufmann M; Dallmann I; Drexler HG
    PLoS One; 2019; 14(12):e0226212. PubMed ID: 31825998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia.
    Jankovic D; Gorello P; Liu T; Ehret S; La Starza R; Desjobert C; Baty F; Brutsche M; Jayaraman PS; Santoro A; Mecucci C; Schwaller J
    Blood; 2008 Jun; 111(12):5672-82. PubMed ID: 18388181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing hyperactivated BAP1 attenuates mutant ASXL1-driven myeloid malignancies in human haematopoietic cells.
    Bai J; Chen Z; Chen C; Zhang M; Zhang Y; Song J; Yuan J; Jiang X; Xing W; Yang J; Bai J; Zhou Y
    Cancer Lett; 2021 Oct; 519():78-90. PubMed ID: 34186160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hhex induces promyelocyte self-renewal and cooperates with growth factor independence to cause myeloid leukemia in mice.
    Jackson JT; Ng AP; Shields BJ; Haupt S; Haupt Y; McCormack MP
    Blood Adv; 2018 Feb; 2(4):347-360. PubMed ID: 29453249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.
    Brandts CH; Sargin B; Rode M; Biermann C; Lindtner B; Schwäble J; Buerger H; Müller-Tidow C; Choudhary C; McMahon M; Berdel WE; Serve H
    Cancer Res; 2005 Nov; 65(21):9643-50. PubMed ID: 16266983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and Characterization of Induced Pluripotent Stem Cells Carrying An ASXL1 Mutation.
    Wang W; Zhang X; Li Y; Shen J; Li Y; Xing W; Bai J; Shi J; Zhou Y
    Stem Cell Rev Rep; 2024 Oct; 20(7):1889-1901. PubMed ID: 38884929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular mechanisms by which the mutant ASXL1/BAP1 complex aggravates myeloid leukemia].
    Asada S
    Rinsho Ketsueki; 2020; 61(4):392-405. PubMed ID: 32378586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9-mediated ASXL1 mutations in U937 cells disrupt myeloid differentiation.
    Wu ZJ; Zhao X; Banaszak LG; Gutierrez-Rodrigues F; Keyvanfar K; Gao SG; Quinones Raffo D; Kajigaya S; Young NS
    Int J Oncol; 2018 Apr; 52(4):1209-1223. PubMed ID: 29532865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.
    Balasubramani A; Larjo A; Bassein JA; Chang X; Hastie RB; Togher SM; Lähdesmäki H; Rao A
    Nat Commun; 2015 Jun; 6():7307. PubMed ID: 26095772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.